Foley secured three significant inter partes review victories on behalf of Supernus Pharmaceuticals, Inc. and Galderma S.A. for a pharmaceutical product, which represents one of the first inter partes reviews to reach a final decision in favor of the patent owner, where the patents were the subject of a parallel Hatch-Waxman patent litigation. The inter partes reviews were filed by a “generic” company that filed an Abbreviated New Drug application to market a generic version of the product Oracea®.
The Foley team, led by Stephen Maebius, included Andrew Baluch, George Quillin, and Sunit Talapatra.
